Contact this trialFirst, we need to learn more about you.
Monoclonal Antibodies
Atezolizumab + Bevacizumab + Y-90 TARE for Liver Cancer
Recruiting1 awardPhase 2
Nashville, Tennessee
This trial is looking at whether adding bevacizumab and atezolizumab to Y90 TARE improves treatment of unresectable advanced stage HCC.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service